| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLA1 |
| Uniprot No | Q53H76 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-456aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSDAPPTPQ PKCADFQSAN LFEGTDLKVQ FLLFVPSNPS CGQLVEGSSD LQNSGFNATL GTKLIIHGFR VLGTKPSWID TFIRTLLRAT NANVIAVDWI YGSTGVYFSA VKNVIKLSLE ISLFLNKLLV LGVSESSIHI IGVSLGAHVG GMVGQLFGGQ LGQITGLDPA GPEYTRASVE ERLDAGDALF VEAIHTDTDN LGIRIPVGHV DYFVNGGQDQ PGCPTFFYAG YSYLICDHMR AVHLYISALE NSCPLMAFPC ASYKAFLAGR CLDCFNPFLL SCPRIGLVEQ GGVKIEPLPK EVKVYLLTTS SAPYCMHHSL VEFHLKELRN KDTNIEVTFL SSNITSSSKI TIPKQQRYGK GIIAHATPQC QINQVKFKFQ SSNRVWKKDR TTIIGKFCTA LLPVNDREKM VCLPEPVNLQ ASVTVSCDLK IACV |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PLA1重组蛋白的3篇代表性文献摘要(文献信息为模拟示例)：
1. **《重组人PLA1的异源表达及其酶学性质研究》- 作者：张某某等**
摘要：通过在大肠杆菌中重组表达人源PLA1蛋白，优化表达条件并纯化获得高活性酶。研究发现重组PLA1对磷脂酰胆碱底物具有特异性水解活性，最适反应温度为37℃，pH 8.0.
2. **《Structure and function of a novel PLA1 from venom of wasp》- 作者：Chen X et al.**
摘要：首次从胡蜂毒液中克隆并重组表达了新型PLA1蛋白，解析其晶体结构，揭示了其独特的底物结合口袋结构，并证明该酶在诱导炎症反应中起关键作用。
3. **《重组PLA1在脂质代谢疾病模型中的治疗潜力》- 作者：Wang Y et al.**
摘要：利用哺乳动物细胞系统表达重组PLA1.通过动物实验证明其能显著降低动脉粥样硬化模型小鼠的血清低密度脂蛋白水平，提示其在治疗脂质代谢紊乱中的潜在应用价值。
(注：以上文献为基于领域知识的模拟描述，实际文献需通过PubMed/Web of Science等平台检索。)
PLA1 (Phospholipase A1) is a key enzyme belonging to the phospholipase family, primarily catalyzing the hydrolysis of phospholipids at the sn-1 position to generate free fatty acids and lysophospholipids. It plays critical roles in lipid metabolism, membrane remodeling, and cell signaling. Naturally occurring in various organisms, including mammals, insects, and microorganisms, PLA1 has garnered significant attention for its involvement in physiological and pathological processes such as inflammation, blood coagulation, and neurodegenerative diseases. For instance, in humans, specific isoforms like phosphatidylserine-specific phospholipase A1 (PS-PLA1) are implicated in regulating immune responses and maintaining cellular homeostasis.
The development of recombinant PLA1 proteins through genetic engineering has enabled large-scale production and functional studies. By cloning PLA1 genes into expression systems (e.g., E. coli, yeast, or mammalian cells), researchers obtain purified enzymes with consistent activity, bypassing challenges associated with isolating native proteins from biological tissues. Recombinant PLA1 retains catalytic properties and structural features of its natural counterpart, making it invaluable for structural biology (e.g., X-ray crystallography) and mechanistic studies.
Applications of recombinant PLA1 span biomedical research, industrial biotechnology, and therapeutics. It serves as a tool to investigate lipid-mediated signaling pathways or to develop enzyme inhibitors for treating PLA1-related disorders. In the food and cosmetics industries, recombinant PLA1 is used to modify phospholipids for improved emulsification or bioactive molecule production. Additionally, its role in generating lipid mediators highlights potential therapeutic uses in modulating inflammatory diseases or thrombotic conditions. Ongoing research continues to explore its molecular interactions and therapeutic targeting, underscoring PLA1's versatility as both a biological catalyst and a drug discovery target.
×
